Expanding the clinical phenotype of DYNC1H1 -associated mutations: a Chinese family with autosomal dominant complex hereditary spastic paraplegia Authors: Xiaoqin Yuan, Shanshan Zhang, Yufeng Tang Published: 2025 ABSTRACT AbstractBackgroundHereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative diseases. To date, at least 84 distinct loci (SPGs) and 67 causative genes have been identified. Even though the number of known causative genes is constantly increasing, a substantial portion of patients remains without a molecular diagnosis. Variants in the dynein, cytoplasmic 1, heavy chain 1(DYNC1H1)gene have been reported to cause a range of neurogenetic diseases, including spinal muscular atrophy (SMA), Charcot-Marie-Tooth disease (CMT), and cortical malformations. This study aims to characterize the clinical spectrum of DYNC1H1-related disorders by reporting a rare missense variant (c.13763 C > T, p.Thr4588Met) identified in a Chinese family with autosomal dominant (AD) complex HSP.MethodsThe affected individuals underwent a comprehensive neurological evaluation, including assessment of clinical features, laboratory testing, brain magnetic resonance imaging (MRI), and electrophysiological studies. The repetition/deletions in the SPAST, ATL1 gene were detected using multiplex ligation-dependent probe analysis (MLPA). Whole-exome sequencing (WES) was performed to identify the disease-causing mutation in the proband, which was subsequently validated by Sanger sequencing in the proband and his parents. In silico analysis was performed to predict the pathogenicity of the identified mutations.ResultsA heterozygous missense variant (c.13763 C > T, p.Thr4588Met) in the DYNC1H1 gene was identified, which was classified as likely pathogenic according to ACMG guidelines. The family was affected by autosomal dominant complex HSP, presenting with marked spastic paraplegia and ataxia. In silico analyses (e.g., using PolyPhen-2, PROVEAN, Mutation Taster, and CADD) indicated a deleterious effect on protein function.ConclusionsThis study reports a rare DYNC1H1 variant associated with autosomal dominant (AD) complex HSP, expanding the mutational and phenotypic spectrum of DYNC1H1-related disorders.Keywords: DYNC1H1, Hereditary spastic paraplegia, Cerebellar ataxia, Autosomal dominant, Whole-exome sequencing, Variant Introduction Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative diseases. Based on clinical manifestations, HSPs have been divided into pure or complicated forms [1]. Pure form presented with slowly progressive spastic paraplegia and weakness of the lower limbs and occasionally accompanied by urinary symptoms. Additional system involvement such as cognitive impairment, epilepsy, ataxia, basal ganglia symptoms, peripheral neuropathy, visual or auditory disturbances were defined as complicated forms of HSP. The prevalence of HSP is 2 to 10 per 100,000 [2]. The mode of inheritance can be autosomal dominant (AD), autosomal recessive (AR), X-linked, rarely mitochondrial or de novo [3]. To date, 84 loci and 67 causative genes have been identified for HSP [4]. Even though the number of known causative genes is constantly increasing, a substantial portion of patients remains without a molecular diagnosis. Mutations in the dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1) gene has been implicated in a wide spectrum of disorders including autosomal dominant lower extremity-predominant spinal muscular atrophy-1 (SMALED1) [5], Charcot-Marie-Tooth disease (CMT) [6], severe intellectual disability [7], malformations of cortical development [8], congenital lower motor neuron disease associated with focal areas of cortical malformation (SMA-FACM) [9], and epileptic encephalopathies [10]. The identification of a de novo DYNC1H1 mutation in a complex HSP patient was reported, suggesting that DYNC1H1 mutations may cause not only lower, but also upper motor neuron disease [11]. DYNC1H1 encodes a large protein, one of two known cytoplasmic heavy chain dyneins, which forms a dimer and is involved in the microtubule transport system [12]. DYNC1H1 serves as an essential component of the cytoplasmic dynein complex in neurons, facilitating retrograde cargo transport in axons and dendrites, and thereby playing a vital role in neuronal development, morphology, and survival [13]. In recent years, whole-exome sequencing (WES) has emerged as a highly efficient diagnostic approach for investigating pathogenic variants in neurogenetic disorders. By characterizing a DYNC1H1 variant in an AD cHSP family, this study aims to expand the phenotype of DYNC1H1-related disorders and provide further evidence for the role of cytoplasmic dynein in HSP. To our knowledge, this is the first report of a DYNC1H1 mutation associated with autosomal dominant complex HSP. Materials and methods Patients The proband, an 18-year-old male patient, and his father were referred to our clinic and complained about gait abnormalities and difficulty in walking. They underwent a standardized neurological examination and were ascertained independently by another neurologist. Detailed information about onset age, disease progression and family history was recorded. Peripheral blood samples from the proband and his parents were obtained with informed consent. Genetic analysis DNA was extracted from peripheral leucocytes using standard procedures. At first, we performed multiplex ligation-dependent probe amplification (MLPA) on the proband to detect deletions and duplications in the SPAST and ATL1 genes. (Kingmed Center for Clinical Laboratory CO., LTD, Guangzhou, China). Whole-exome sequencing (WES) was performed using the Agilent SureSelectTM Human All Exome V6 kit (Agilent Technologies Inc, Canada) on an Illumina HiSeq2500 platform. The mean coverage depth for the WES was 160x. The percentage of targets covered at least 30x was 97.83%. Raw sequencing data (FASTQ files) were processed using the Illumina DRAGEN for secondary analysis. Subsequently, identified variants were filtered based on a minor allele frequency (MAF) threshold of ≤ 1% in population databases including dbSNP, gnomAD, and the 1000 Genomes Project. Following initial filtering, the remaining variants were annotated using the ClinVar database to identify any previously reported classifications of “Pathogenic” or “Likely Pathogenic. Detected variants were confirmed by segregation analysis using Sanger sequencing. Bioinformatics analysis The GRCh38/hg38 human reference genome was used for all analyses. Whole-exome variants were annotated using public databases, including HGMD (http://www.hgmd.cf.ac.uk/ac/index.php), OMIM (https://www.omim.org/), dbSNP (http://www.ncbi.nlm.nih.gov/snp), gnomAD v4.1.0(http://gnomad.broadinstitute.org/), 1000 Genomes Project (http://browser.1000genomes.org), and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar). Variants with a population allele frequency ≤ 1% were retained for further analysis. The potential pathogenicity of these rare variants was predicted using in silico tools: PROVEAN (http://provean.jcvi.org/index.php), PolyPhen-2 v2.2.3 (http://genetics.bwh.harvard.edu/pph2/index.shtml), Mutation Taster (https://www.mutationtaster.org/), and CADD v.1.7 (https://cadd.gs.washington.edu/snv). The structural impact of the identified missense variant was assessed with Missense3D (http://missense3d.bc.ic.ac.uk/~missense3d/). Finally, candidate variants were interpreted and classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines [14]. Results Clinical characteristics The proband, an 18-year-old male, developed slowly progressive spasticity and mild weakness of the lower limbs at the age of 9. His neonatal period was unremarkable. Psychomotor milestones were normally achieved and he was able to walk at the age of 1 year. He finished junior high school and then quitted because of gait abnormality. Neurological examination revealed a scissor gait. Motor strength was preserved in all four limbs. Muscle tone was normal in the upper limbs, whereas the lower limbs exhibited marked spasticity, accompanied by brisk tendon reflexes, bilateral ankle clonus, and a positive Babinski sign. Mild limb ataxia and slight postural tremor in upper limbs were observed. Currently, he can walk slowly with a spastic gait. He had no cognitive decline, psychiatric symptoms, sensory deficits, bladder dysfunction, or epileptic seizure. Laboratory tests including complete blood count, electrolytes, glucose, thyroid function, serum vitamin B12, and folate were all within normal limits. Brain magnetic resonance imaging (MRI) revealed mild cerebellar atrophy (Fig. 1A). Nerve conduction studies were normal. Brain magnetic resonance imaging scan (MRI) of the proband (A) and his father (B). The arrows indicate cerebellar atrophy His family history showed an autosomal-dominant manner (Fig. 2). His father, a 43-year-old man (II-1), also showed prominent spastic paraplegia. He first noticed stiffness of legs at the age of 32. His gait disturbance was progressed slowly since then. He was not able to walk independently and needed a crutch at the age of 38. Neurological examination revealed prominent upper motor neuron signs predominantly in the lower limbs, characterized by severe spasticity with flexed knees, markedly increased muscle tone, brisk deep tendon reflexes, bilateral ankle clonus, and positive Babinski signs. Motor strength was normal in all four limbs, and upper limb tone was unremarkable. The examination also identified cerebellar involvement, including slurred speech and obvious limb ataxia. No cognitive decline, sensory deficits, or bladder dysfunction were observed. MRI showed moderate cerebellar atrophy (Fig. 1B). The proband’s grandmother had abnormal gait when she was young and passed away in her fifties; the exact cause of death was unknown. Pedigree of the family (proband indicated by black arrow) and Sanger validation of the DYNC1H1 variant (NM_001376.5: c.13763 C > T, p.Thr4588Met). The proband and his father are heterozygous for the mutation, while the mother exhibits the wild-type sequence Genetic findings Whole exome sequencing of the proband detected a missense variant located in the DYNC1H1 gene on chromosome 14q32: NM_001376.5: exon77: c.13,763 C > T, p. (Thr4588Met). It was found at an extremely low frequency in public databases (gnomAD: 0.00001488; dbSNP: T = 0.00000; TOPMed: 7.964 × 10⁻⁶) and, although annotated in ClinVar for Charcot-Marie-Tooth disease (CMT), lacked supporting published evidence (VCV002911947.2). The variant was confirmed by Sanger sequencing. Segregation analysis showed that it was inherited from the affected father and was absent in the mother, consistent with autosomal dominant inheritance (Fig. 2). The c.13,763 C > T variant was predicted to be deleterious by PROVEAN with a score of -3.99, probably damaging by PolyPhen-2 (score = 0.977), deleterious by Mutation Taster, and pathogenic by CADD with a score of 24.4. Using Missense3D, the p.Thr4588Met substitution was assessed for its structural impact and found to introduce a buried H-bond breakage, likely causing structural destabilization. Comparative protein structures of wild-type and mutant DYNC1H1 were generated with Missense3D (Fig. 3). Three-dimensional(3D) structures of the DYNC1H1 wild-type protein (A) and the mutant protein (B). The blue represents the Thr residue. The red represents the Met residue Based on these findings and in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines, the variant was classified as “likely pathogenic” as it belongs to PM2 (its extremely low frequency in the gnomAD control population), PP1 (Co-segregation within the family in a Mendelian disorder), PP2(Missense variant in a gene where such variants are a common disease mechanism), PP3 (Multiple lines of computational evidence support a deleterious effect on the gene or gene product). Discussion This study identified a rare heterozygous missense variant in DYNC1H1 (NM_001376.4: c.13763 C > T, p.Thr4588Met) in a Chinese family presenting with prominent spastic paraplegia and cerebellar ataxia, in the absence of cognitive decline or peripheral neuropathy. This is the first report of a HSP family with autosomal dominant inheritance caused by a DYNC1H1 mutation. Mutations in the DYNC1H1 gene have been reported to cause a broad spectrum of disorders involving both the neuromuscular disorders (NMDs) and neurodevelopmental (NDD). NMDs primarily affect the peripheral nervous system (e.g., CMT2O and SMALED1), while NDDs involve the central nervous system and feature intellectual disability, cortical malformations, hypotonia, and developmental delay [15]. A large European study conducted whole-exome sequencing (WES) on 1024 samples from patients with motor neuron disorders and related conditions, including 400 cases of pure and complex HSP. The study identified a de novo mutation in DYNC1H1 (c.3185 A > G, p.Asp1062Gly) in an individual diagnosed with complex HSP. The patient presented with spastic paraplegia accompanied by intellectual disability, epilepsy, and cataracts. Brain MRI revealed a thin corpus callosum (TCC). To our knowledge, this represents the first and only reported case of HSP associated with a DYNC1H1 mutation to date [11]. In the present study, we report a rare missense mutation in DYNC1H1 (c.13763 C > T; p.Thr4588Met) in a Chinese family with complex HSP. Pedigree analysis was consistent with autosomal dominant inheritance. Both the proband and his father presented with marked spastic paraplegia accompanied by mild ataxia. Brain MRI revealed cerebellar atrophy in the affected individuals. Previous studies reported that half of the patients (3/6) with DYNC1H1 mutations exhibited a mildly reduced anterior cerebellar vermis [8, 16]. Collectively, these findings significantly expand the mutational and phenotypic spectrum of DYNC1H1-related disorders, underscoring its role in complex HSP and highlighting the emerging association with cerebellar involvement. The DYNC1H1 gene, located on chromosome 14q32, encodes the cytoplasmic dynein 1 heavy chain 1—the largest and highly conserved subunit of the cytoplasmic dynein complex. This subunit plays a critical role in mediating the binding and translocation of the dynein complex along microtubules through its large motor domain [12]. DYNC1H1 consists of four major regions: tail domains (amino acid residues 1-1373 and 4222–4646), linker domain (aa 1374–1867), motor domains with AAA domains (ATPases associated with a variety of cellular activities, aa 1868–3168 and 3553–4221), and the stalk or microtubule-binding domain (MTBD, aa 3169–3552) [17]. The DYNC1H1 mutation (c.13763 C > T; p.Thr4588Met) identified in this study is located within the C-terminal tail domain. The Stem/C-terminal domain of DYNC1H1 (approximately residues 3800–4646) interacts with the dynein-activating complex dynactin and the Lis1/NudE family proteins, thereby regulating motor activity and anchoring [18, 19]. The distal tail also harbors a Lis1-binding site that is essential for neuronal migration [20]. A recently published study analyzed 47 patients with pathogenic DYNC1H1 variants from 43 families using standardized clinical assessments and follow-up [15]. The research identified novel neurological and multisystem features—including autonomic dysfunction, sensory neuropathy, immunodeficiency, and a biphasic disease course. These findings broaden the clinical spectrum of DYNC1H1-related disorders, and underscore the role of impaired intracellular trafficking in disease progression. Mechanistic studies of pathogenic DYNC1H1 mutations have been conducted across multiple model systems. Missense mutations within the cytoplasmic dynein stem domain give rise to mouse models such as LOA, Cra, and Swl, which exhibit impaired retrograde transport, ultimately leading to neurodegeneration, defective neuronal migration, and aberrant axon growth [12, 21]. Mutations in the motor domain of DYNC1H1 are associated with motor deficits, cortical malformations, developmental and epileptic encephalopathies, and intellectual disability [22]. Although genotype–phenotype correlations vary among different DYNC1H1 mutations, their precise effects on dynein function are not fully elucidated, underscoring the need for further investigations. This study has several limitations. First of all, the pathogenicity of the variant was predicted based on genetic analyses, functional validation through in vitro or in vivo experiments was not conducted to confirm the underlying mechanism. Secondly, the sample size was relatively small. Subsequent studies will aim to screen a larger cohort of patients with a clinical diagnosis of HSP who currently lack a molecular diagnosis. Conclusion In conclusion, we describe the first familial case series of complex HSP caused by a rare variant in DYNC1H1 (c.13763 C > T; p.Thr4588Met). Our findings provide valuable insights into the genetic and clinical variability of DYNC1H1-related diseases and underscore the importance of considering this gene in the diagnostic evaluation of patients with complex HSP—especially those with autosomal dominant inheritance and cerebellar involvement. Acknowledgements The authors thank the patient and his family members for their participation in the study. Authors’ contributions XQY conceptualized and designed the study. SSZ collected the data. YFT revised the manuscript. All authors read and approved the final manuscript. Funding No funding. Data availability The details of the variant (c.13763 C> T; p.Thr4588Met) analyzed in this study have been submitted to the ClinVar database ( SUB15661125 - Review & Submit | ClinVar Submission Wizard | Submission Portal ) with the Submission ID : SUB15661125. Declarations Ethics approval and consent to participate The study was approved by the Ethics Committee of Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China. Written informed consents were obtained from all the individuals included in the study. Consent for publication Written informed consent was obtained from all participants and patients for the publication of identifiable materials, including images and personal or clinical details. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The details of the variant (c.13763 C> T; p.Thr4588Met) analyzed in this study have been submitted to the ClinVar database ( SUB15661125 - Review & Submit | ClinVar Submission Wizard | Submission Portal ) with the Submission ID : SUB15661125.